Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility and Safety of Sequential Tapering and Discontinuation of Beta-blockers in Patients With Obstructive Hypertrophic Cardiomyopathy After Achieving Hemodynamic Targets With Mavacamten: a Multicenter, Randomized, Open-label, Parallel-group, Non-inferiority Trial (STEP-oHCM)

NCT07815301 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT07815301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility and Safety of Sequential Tapering and Discontinuation of Beta-blockers in Patients With Obstructive Hypertrophic Cardiomyopathy After Achieving Hemodynamic Targets With Mavacamten: a Multicenter, Randomized, Open-label, Parallel-group, Non-inferiority Trial (STEP-oHCM)
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2028
Enrollment
286 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy (ohcm)